AVIR Atea Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AVIR

Price (delayed)

$4.41

Market cap

$352.92M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.11

Enterprise value

$274.24M

?
Relative Growth: Rel. Growth: 2
Relative Strength: Rel. Strength: 64
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging its deep understanding ...

Highlights
The debt has dropped by 56% year-on-year and by 25% since the previous quarter
Atea Pharmaceuticals's quick ratio has shrunk by 61% YoY
The company's equity fell by 43% YoY and by 15% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://ateapharma.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of AVIR

AVIR stock price

How has the Atea Pharmaceuticals stock price performed over time
Intraday
4.75%
1 week
-6.77%
1 month
-22.63%
1 year
36.53%
YTD
23.53%
QTD
-18.03%

Financial performance

How have Atea Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$189.85M
Net income
-$169.52M
Gross margin
N/A
Net margin
N/A
Atea Pharmaceuticals's net income has decreased by 22% YoY and by 7% from the previous quarter
The operating income is down by 17% YoY and by 5% QoQ

Price vs fundamentals

How does AVIR's price correlate with its fundamentals

Growth

What is Atea Pharmaceuticals's growth rate over time

Valuation

What is Atea Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.5
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Atea Pharmaceuticals's EPS has decreased by 28% YoY and by 9% QoQ
The company's equity fell by 43% YoY and by 15% QoQ
AVIR's P/B is 31% higher than its 5-year quarterly average of 1.1 and 31% higher than its last 4 quarters average of 1.1

Efficiency

How efficient is Atea Pharmaceuticals business performance
AVIR's return on invested capital has dropped by 89% year-on-year and by 25% since the previous quarter
The company's return on equity has shrunk by 82% YoY and by 23% QoQ
The ROA has shrunk by 76% YoY and by 21% QoQ

Dividends

What is AVIR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVIR.

Financial health

How did Atea Pharmaceuticals financials performed over time
Atea Pharmaceuticals's quick ratio has shrunk by 61% YoY
The current ratio has dropped by 60% year-on-year
The debt is 100% smaller than the equity
The debt has dropped by 56% year-on-year and by 25% since the previous quarter
The company's equity fell by 43% YoY and by 15% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.